BK

Bobby Kniffin

Director, Key Accounts Oncology/ophthalmology at Coherus BioSciences

Bobby Kniffin has an extensive work experience in the pharmaceutical and education sectors. Bobby started their career as a high school teacher and baseball coach at Rincon/University High School in 1996. Bobby then transitioned to the pharmaceutical industry, working at Merck as a sales representative, specialty sales representative, sales trainer, and regional analyst. Bobby sold various pharmaceutical products and achieved success as a President's Club winner.

Afterwards, Bobby joined American Regent and served as a territory manager and later as a regional sales manager. Bobby was responsible for launching a new IV Iron product and managing a team of Territory Managers.

Bobby then worked at Daiichi Sankyo, Inc. in various roles such as regional sales director, national strategic planner, and regional account manager. Bobby played a crucial role in strategic planning, business reviews, and key opinion leader development.

Currently, Bobby is employed at Coherus BioSciences as the Director of Key Accounts in the Oncology/Ophthalmology division. Bobby previously held the position of Senior Oncology Account Manager, where they successfully conducted contract sales for a biosimilar product, Udenyca, in Arizona.

With a diverse background in teaching, pharmaceutical sales, and key account management, Bobby Kniffin has developed a strong skill set and expertise in the healthcare industry.

Bobby Kniffin completed their MBA in Management at the University of Denver - Daniels College of Business from 2001 to 2003. Prior to that, they obtained a B.S. in Health Education from Northern Arizona University between 1993 and 1995. Bobby also attended the University of Arizona from 1990 to 1993, but no degree or field of study was specified.

Links

Previous companies

Merck logo
Daiichi Sankyo logo

Timeline

  • Director, Key Accounts Oncology/ophthalmology

    April, 2023 - present

  • Senior Oncology Account Manager

    October, 2018

View in org chart